Who are Nab-paclitaxel+ trastuzumab+ patuzumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nab-paclitaxel-trastuzumab-patuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Nab-paclitaxel+ trastuzumab+ patuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-paclitaxel+ trastuzumab+ patuzumab (Nab-paclitaxel+ trastuzumab+ patuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor and HER2-targeting monoclonal antibodies. Area: Oncology.

phase 3 Microtubule inhibitor and HER2-targeting monoclonal antibodies Microtubules and HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nab-paclitaxel+ trastuzumab+ patuzumab (Nab-paclitaxel+ trastuzumab+ patuzumab) — Henan Cancer Hospital. Nab-paclitaxel is a microtubule inhibitor that disrupts cell division, while trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nab-paclitaxel+ trastuzumab+ patuzumab TARGET	Nab-paclitaxel+ trastuzumab+ patuzumab	Henan Cancer Hospital	phase 3	Microtubule inhibitor and HER2-targeting monoclonal antibodies	Microtubules and HER2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor and HER2-targeting monoclonal antibodies class)

Henan Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nab-paclitaxel+ trastuzumab+ patuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/nab-paclitaxel-trastuzumab-patuzumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab